Walleye Capital
RVNC

Walleye Capital’s Revance Therapeutics, Inc. RVNC Stock Holding History

Walleye Capital’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-49,100
Closed -$126K – 6023
2024
Q2 		$126K Sell
49,100
-18,800
-28% -$64.2K ﹤0.01% 4593
2024
Q1 		$334K Buy
67,900
+44,200
+186% +$262K ﹤0.01% 3554
2023
Q4 		$208K Buy
23,700
+18,600
+365% +$152K ﹤0.01% 3647
2023
Q3 		$58.5K Sell
5,100
-2,800
-35% -$53.8K ﹤0.01% 4146
2023
Q2 		$200K Buy
7,900
+2,400
+44% +$74.8K ﹤0.01% 3084
2023
Q1 		$177K Buy
+5,500
New +$171K ﹤0.01% 2561
2019
Q3 		– Sell
-28,000
Closed -$363K – 2333
2019
Q2 		$363K Buy
+28,000
New +$353K 0.04% 651

Other funds holding RVNC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Walleye Capital's RVNC Position: Q4 2024 in Review

Walleye Capital sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2024, closing a stake of 699,621 shares — an estimated $3.63M sold.

Walleye Capital first reported a position in RVNC in Q3 2018 and held it in 17 quarters. The position peaked at $14.1M in Q3 2022. 173 funds tracked by Wall St. Rank hold RVNC as of Q4 2024.

  • Walleye Capital reported no remaining Revance Therapeutics, Inc. position as of Q4 2024 after selling out during the quarter.
  • Walleye Capital sold 699,621 Revance Therapeutics, Inc. shares in Q4 2024, an estimated $3.63M.
  • Walleye Capital first reported a position in Revance Therapeutics, Inc. in Q3 2018 and held it in 17 quarters.
  • Walleye Capital's Revance Therapeutics, Inc. position peaked at $14.1M in Q3 2022.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2024.

Based on Walleye Capital's 13F filing for Q4 2024, filed 13 Feb 2025.